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Background
Inflammatory myopathies (IM) in children comprise a
heterogeneous group of disorders, the most common
being juvenile dermatomyositis and to a lesser degree
juvenile polymyositis.
Aim
To assess the clinical characteristics and treatment
response of a cohort of IM patients.
Methods
Clinical chart review of clinical, laboratory and treat-
ment related parameters of IM patients treated at 2
referral centers for the last 12 years.
Outcome measures included disease remission and
muscular function.
Results
17 IM patients (12F/5M, median age at diagnosis-8years
(2-16years)) were followed for a mean of 6,3years (1-
12years): 3 were labeled as polymyositis and 14 as juve-
nile dermatomyositis.
Positive diagnostic criteria: typical skin lesions-14/17,
proximal muscle weakness-15/17, elevated muscle
enzymes-16/17, EMG-10/10, muscle biopsy-9/9.
Frequent presenting symptoms included: proximal
muscle weakness-16/17, skin lesions-11/17, lethargy-8/
17, fever-7/17. During follow-up, patients presented
with: muscle weakness (17/17), skin lesions (14/17),
lipodystrophy (2/17), arthralgia (6/17), arthritis(4/17),
vasculitis (4/17), gastro-intestinal vasculitis (1/17),
restrictive pulmonary disease (1/17), calcinosis (4/17).
Laboratory: ESR was raised in 6/17, muscle enzymes
in 17/17 (CK-16/17, median-1149; LDH 16/17, median-
875; aldolase-7/17); Positive auto-antibodies: ANA-11/
17, SSA(Ro-52)-2/17; 10/17 underwent muscle biopsy
and 9/17 EMG.
Therapeutic regimens included more commonly ster-
oids, methotrexate (17/17) and CyclosporinA (16/17).
Regarding disease activity, 9/17 patients have inactive
disease, 6 of which are in remission without treatment;
6/17 have permanent loss of muscular function.
Conclusion
IM are potentially severe, incapacitating diseases. All
patients with polymyositis in this series have loss of
muscular function, contrasting with 3/14 of JDM
patients.
About half of this cohort is asymptomatic and it
should be stressed that early diagnosis and aggressive
treatment are important prognostic factors.
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